Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RNAZ

RNAZ - TransCode Therapeutics, Inc. Stock Price, Fair Value and News

$3.76-0.09 (-2.34%)
Delayed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

RNAZ Price Action

Last 7 days

-49.3%

Last 30 days

-66.1%

Last 90 days

-67.5%

Trailing 12 Months

-98.3%

RNAZ RSI Chart

RNAZ Valuation

Market Cap

64.9M

Price/Earnings (Trailing)

-4.35

Price/Sales (Trailing)

979.77

Price/Free Cashflow

-4.09

RNAZ Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RNAZ Fundamentals

RNAZ Revenue

Revenue (TTM)

66.3K

Rev. Growth (Yr)

-56.44%

Rev. Growth (Qtr)

-100%

RNAZ Earnings

Earnings (TTM)

-14.9M

Earnings Growth (Yr)

56.2%

Earnings Growth (Qtr)

55.28%

RNAZ Profitability

Return on Equity

-903.45%

Return on Assets

-379.22%

Free Cashflow Yield

-24.47%

RNAZ Investor Care

Shares Dilution (1Y)

3336.36%

Diluted EPS (TTM)

256.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024870.7K81.7K66.3K0
20231.5M1.9M1.3M923.0K
20220545.7K813.1K1.1M
2021000278.3K
Get all data in R, Python etc through our Historical Stock Data APIs

About TransCode Therapeutics, Inc.

RNAZ
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
 CEO
 WEBSITEtranscodetherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES19

TransCode Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for TransCode Therapeutics, Inc.? What does RNAZ stand for in stocks?

RNAZ is the stock ticker symbol of TransCode Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TransCode Therapeutics, Inc. (RNAZ)?

As of Fri Dec 20 2024, market cap of TransCode Therapeutics, Inc. is 64.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RNAZ stock?

You can check RNAZ's fair value in chart for subscribers.

Is TransCode Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether RNAZ is over valued or under valued. Whether TransCode Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact TransCode Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RNAZ.

What is TransCode Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, RNAZ's PE ratio (Price to Earnings) is -4.35 and Price to Sales (PS) ratio is 979.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RNAZ PE ratio will change depending on the future growth rate expectations of investors.